{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:01:47Z","timestamp":1790694107830,"version":"4.1.0"},"reference-count":213,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7242114"],"award-info":[{"award-number":["7242114"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2025-I2M-QN-004"],"award-info":[{"award-number":["2025-I2M-QN-004"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2025-I2M-C&T-B-054"],"award-info":[{"award-number":["2025-I2M-C&T-B-054"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010097","name":"China Association for Science and Technology","doi-asserted-by":"publisher","award":["2024QNRC001"],"award-info":[{"award-number":["2024QNRC001"]}],"id":[{"id":"10.13039\/100010097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82522069"],"award-info":[{"award-number":["82522069"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473366"],"award-info":[{"award-number":["82473366"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chinese Medical Journal Pulmonary and Critical Care Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.pccm.2026.08.001","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:02:07Z","timestamp":1788984127000},"page":"197-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic vaccines for NSCLC: From mechanisms to clinical translation"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9654-6208","authenticated-orcid":false,"given":"Weijing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiefei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailun","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pccm.2026.08.001_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.pccm.2026.08.001_bib0002","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.pccm.2026.08.001_bib0003","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non\u2013small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0004","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-023-01436-2","article-title":"Emerging evidence and treatment paradigm of non-small cell lung cancer","volume":"16","author":"Liu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101266","article-title":"Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer","volume":"82","author":"Du","year":"2025","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.pccm.2026.08.001_bib0006","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1002\/cncr.35423","article-title":"Top advances of the year: targeted therapy for lung cancer","volume":"130","author":"Makarem","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0007","doi-asserted-by":"crossref","first-page":"7670","DOI":"10.1021\/acs.jmedchem.3c00028","article-title":"Targeting MET: discovery of small molecule inhibitors as non-small cell lung cancer therapy","volume":"66","author":"Wang","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.pccm.2026.08.001_bib0008","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2026.08.001_bib0009","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41571-023-00733-6","article-title":"Rare molecular subtypes of lung cancer","volume":"20","author":"Harada","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0010","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0011","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0012","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/s41571-025-01061-7","article-title":"Treatment of NSCLC after chemoimmunotherapy-are we making headway?","volume":"22","author":"Reck","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0013","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s13046-025-03519-z","article-title":"Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities","volume":"44","author":"Wang","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.pccm.2026.08.001_bib0014","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non\u2013small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nri778","article-title":"Effector and memory T-cell differentiation: implications for vaccine development","volume":"2","author":"Kaech","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0016","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1384","article-title":"mRNA vaccine in cancer therapy: current advance and future outlook","volume":"13","author":"Li","year":"2023","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.pccm.2026.08.001_bib0017","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","article-title":"Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer","volume":"7","author":"Papachristofilou","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105844","article-title":"Innovative therapeutic cancer vaccine PDC\u2217lung01 with or without anti-PD-1: an open-label, dose-escalation phase I\/II study in non-small-cell lung cancer","volume":"10","author":"Vansteenkiste","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.pccm.2026.08.001_bib0019","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","article-title":"Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer","volume":"40","author":"Awad","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pccm.2026.08.001_bib0020","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1158\/2159-8290.CD-24-0158","article-title":"T-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 study","volume":"14","author":"Gainor","year":"2024","journal-title":"Cancer Discov"},{"issue":"8_Supplement_2","key":"10.1016\/j.pccm.2026.08.001_bib0021","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT013","article-title":"Abstract CT013: phase I trial evaluating BNT116, a TAA-encoding mRNA vaccine, in combination with cemiplimab in frail patients with advanced non-small cell lung cancer (NSCLC)","volume":"85","author":"Dziadziuszko","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.pccm.2026.08.001_bib0022","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.pccm.2026.08.001_bib0023","article-title":"Real-world effectiveness of racotumomab as maintenance therapy in advanced non-small cell lung cancer patients","volume":"13","author":"Alfonso Alem\u00e1n","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.pccm.2026.08.001_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103369","article-title":"Evaluation of clinical and safety outcomes of cancer vaccines in patients with advanced non-small cell lung cancer after first-line therapy: a systematic review and meta-analysis","volume":"86","author":"Chen","year":"2025","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.pccm.2026.08.001_bib0025","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1038\/s41467-025-60281-8","article-title":"TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I\/II dose-escalation study","volume":"16","author":"Emmers","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.pccm.2026.08.001_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.pccm.2026.08.001_bib0027","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","article-title":"Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma","volume":"27","author":"Hu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.pccm.2026.08.001_bib0028","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pccm.2026.08.001_bib0029","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1042\/EBC20230001","article-title":"The role of IFN-\u03b3-signalling in response to immune checkpoint blockade therapy","volume":"67","author":"Wong","year":"2023","journal-title":"Essays Biochem"},{"key":"10.1016\/j.pccm.2026.08.001_bib0030","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ijc.34127","article-title":"Cancer-associated fibroblasts in nonsmall cell lung cancer: from molecular mechanisms to clinical implications","volume":"151","author":"Wong","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.623475","article-title":"Monitoring T cells responses mounted by therapeutic cancer vaccines","volume":"8","author":"Lim","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.pccm.2026.08.001_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1090533","article-title":"Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials","volume":"14","author":"McCarthy","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0033","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12943-019-1062-7","article-title":"Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations","volume":"18","author":"Lin","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0034","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1016\/j.vaccine.2016.09.062","article-title":"Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines","volume":"34","author":"Jorritsma","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.pccm.2026.08.001_bib0035","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13046-019-1154-7","article-title":"Cancer DNA vaccines: current preclinical and clinical developments and future perspectives","volume":"38","author":"Lopes","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.pccm.2026.08.001_bib0036","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0037","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41551-025-01344-5","article-title":"Small circular RNAs as vaccines for cancer immunotherapy","volume":"9","author":"Zhang","year":"2025","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.pccm.2026.08.001_bib0038","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1002\/eji.201343324","article-title":"Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation","volume":"43","author":"Rosalia","year":"2013","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0039","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.nano.2018.09.004","article-title":"Protein-based nanoparticles in cancer vaccine development","volume":"15","author":"Neek","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.pccm.2026.08.001_bib0040","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13025","article-title":"Peptide-based therapeutic cancer vaccine: current trends in clinical application","volume":"54","author":"Liu","year":"2021","journal-title":"Cell Prolif"},{"key":"10.1016\/j.pccm.2026.08.001_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2024.101324","article-title":"Cancer vaccines: target antigens, vaccine platforms and preclinical models","volume":"101","author":"Ruzzi","year":"2025","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.pccm.2026.08.001_bib0042","article-title":"Rethinking antigen source: cancer vaccines based on whole tumor cell\/tissue lysate or whole tumor cell","volume":"10","author":"Diao","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.pccm.2026.08.001_bib0043","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.ejca.2015.07.035","article-title":"A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer","volume":"51","author":"Giaccone","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0044","article-title":"Dendritic cell immunotherapy advances for solid tumors: vaccination and modulation","volume":"6","author":"Clayton","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.pccm.2026.08.001_bib0045","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000329","article-title":"TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma","volume":"8","author":"Keersmaecker","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0046","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pccm.2026.08.001_bib0047","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-023-01408-5","article-title":"Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases","volume":"8","author":"Wang","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.pccm.2026.08.001_bib0048","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316591","article-title":"Personalized cancer vaccines go viral: viral vectors in the era of personalized immunotherapy of cancer","volume":"24","author":"Secl\u00ec","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pccm.2026.08.001_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2025.101994","article-title":"Oncolytic virotherapy: sparking durable anti-tumor immunity through microenvironment modulation","volume":"80","author":"Kollmann","year":"2025","journal-title":"Semin Immunol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0050","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41417-025-00884-x","article-title":"Chimeric Ad5\/35 oncolytic adenovirus overcome preexisting neutralizing antibodies and enhance tumor targeting efficiency","volume":"32","author":"Dai","year":"2025","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.pccm.2026.08.001_bib0051","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.4049\/jimmunol.1501657","article-title":"Landscape of tumor antigens in T cell immunotherapy","volume":"195","author":"Ilyas","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0052","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00269","article-title":"CIMAvax-EGF: a new therapeutic vaccine for advanced non-small cell lung cancer patients","volume":"8","author":"Saavedra","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0053","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1158\/1078-0432.CCR-03-0817","article-title":"A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins","volume":"11","author":"Idenoue","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pccm.2026.08.001_bib0054","first-page":"3387","article-title":"HER2\/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer","volume":"54","author":"Yoshino","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.pccm.2026.08.001_bib0055","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0056","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1255799","article-title":"Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0057","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12770","article-title":"The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer","volume":"53","author":"Xu","year":"2020","journal-title":"Cell Prolif"},{"key":"10.1016\/j.pccm.2026.08.001_bib0058","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1089\/hum.2014.141","article-title":"Superior immunologic and therapeutic efficacy of a xenogeneic genetic cancer vaccine targeting carcinoembryonic human antigen","volume":"26","author":"Aurisicchio","year":"2015","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.pccm.2026.08.001_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110888","article-title":"A review on development of MUC1-based cancer vaccine","volume":"132","author":"Gao","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pccm.2026.08.001_bib0060","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jtho.2021.01.1624","article-title":"The current lung cancer neoantigen landscape and implications for therapy","volume":"16","author":"Ye","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0061","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","article-title":"A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results","volume":"30","author":"Rappaport","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.pccm.2026.08.001_bib0062","article-title":"A universal strategy of anti-tumor mRNA vaccine by harnessing \u201coff-the-shelf\u201d immunity","volume":"12","author":"Fu","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.pccm.2026.08.001_bib0063","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","article-title":"Recent advances in therapeutic cancer vaccines","volume":"25","author":"Zaidi","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0064","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.pccm.2026.08.001_bib0065","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.annonc.2021.09.021","article-title":"Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer","volume":"33","author":"Federico","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0066","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jtho.2016.01.015","article-title":"The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non\u2013small cell lung cancer","volume":"11","author":"Bremnes","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0067","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1158\/1078-0432.CCR-18-3803","article-title":"Tumor-infiltrating lymphocytes\u2014location for prognostic evaluation","volume":"25","author":"Peled","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pccm.2026.08.001_bib0068","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2018.78.1963","article-title":"Tumor mutation burden as a biomarker in resected non-small-cell lung cancer","volume":"36","author":"Devarakonda","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0069","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.pccm.2026.08.001_bib0070","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2026.08.001_bib0071","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.pccm.2026.08.001_bib0072","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41392-024-02087-6","article-title":"Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial","volume":"9","author":"Zhong","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.pccm.2026.08.001_bib0073","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00262-016-1947-x","article-title":"Rejection versus escape: the tumor MHC dilemma","volume":"66","author":"Garrido","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.pccm.2026.08.001_bib0074","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd6971","article-title":"Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non\u2013small cell lung cancers","volume":"7","author":"Han","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.pccm.2026.08.001_bib0075","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41467-024-45361-5","article-title":"Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy","volume":"15","author":"Han","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.pccm.2026.08.001_bib0076","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.pccm.2026.08.001_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2026.103695","article-title":"Molecular profiling across 80,000 patients with lung cancer","volume":"21","author":"Russo","year":"2026","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0078","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jtho.2017.03.010","article-title":"Lung adenocarcinoma and squamous cell carcinoma gene expression subtypes demonstrate significant differences in tumor immune landscape","volume":"12","author":"Faruki","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0079","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41571-022-00718-x","article-title":"At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC","volume":"20","author":"Otano","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0080","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41571-025-01021-1","article-title":"Tumour and microenvironment crosstalk in NSCLC progression and response to therapy","volume":"22","author":"Rahal","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0081","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","article-title":"STK11\/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment","volume":"76","author":"Koyama","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.pccm.2026.08.001_bib0082","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pccm.2026.08.001_bib0083","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","article-title":"CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors","volume":"635","author":"Skoulidis","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.pccm.2026.08.001_bib0084","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.pccm.2026.08.001_bib0085","unstructured":"U.S. Food and Drug Administration. Clinical Considerations for Therapeutic Cancer Vaccines: Guidance for Industry. Rockville: U.S. Food and Drug Administration, 2011. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-considerations-therapeutic-cancer-vaccines [Accessed on April 9, 2026]."},{"key":"10.1016\/j.pccm.2026.08.001_bib0086","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2026.08.001_bib0087","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pccm.2026.08.001_bib0088","article-title":"Therapeutic vaccines for advanced non-small cell lung cancer","volume":"2024","author":"Cort\u00e9s-Jofr\u00e9","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pccm.2026.08.001_bib0089","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"issue":"15_suppl","key":"10.1016\/j.pccm.2026.08.001_bib0090","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.7500","article-title":"START: a phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer","volume":"31","author":"Butts","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0091","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-020-00448-5","article-title":"Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer","volume":"6","author":"Ding","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.pccm.2026.08.001_bib0092","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11912-017-0625-2","article-title":"Cancer clonal theory, immune escape, and their evolving roles in cancer multi-agent therapeutics","volume":"19","author":"Messerschmidt","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.pccm.2026.08.001_bib0093","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0094","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105897","article-title":"Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 \u226550%","volume":"10","author":"De Giglio","year":"2025","journal-title":"ESMO Open"},{"issue":"15_suppl","key":"10.1016\/j.pccm.2026.08.001_bib0095","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.3092","article-title":"Systematic approach for development of new immunotherapeutics for lung cancers through cancer genomics analysis","volume":"31","author":"Daigo","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0096","doi-asserted-by":"crossref","first-page":"26","DOI":"10.21037\/atm-21-5831","article-title":"A narrative review of the emerging role of lymphocyte antigen 6 complex locus K in cancer: from basic research to clinical practice","volume":"10","author":"Guo","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.pccm.2026.08.001_bib0097","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1479-5876-11-97","article-title":"Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer","volume":"11","author":"Suzuki","year":"2013","journal-title":"J Transl Med"},{"key":"10.1016\/j.pccm.2026.08.001_bib0098","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.clim.2016.03.015","article-title":"Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors","volume":"166\u2013167","author":"Murahashi","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0099","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1200\/JCO.22.00096","article-title":"Safety, immunogenicity, and 1-year efficacy of universal cancer peptide\u2013based vaccine in patients with refractory advanced non\u2013small-cell lung cancer: a phase Ib\/phase IIa de-escalation study","volume":"41","author":"Adot\u00e9vi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.pccm.2026.08.001_bib0100","first-page":"A626","article-title":"598 first in human study of S-488210\/S-488211, a cancer peptide vaccine, in patients with advanced solid tumours","volume":"10","author":"Linch","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0101","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1023023","article-title":"Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors \u2013 a phase I trial","volume":"13","author":"Lorentzen","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0102","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40425-017-0274-x","article-title":"Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC","volume":"5","author":"Tosch","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0103","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/21645515.2017.1373921","article-title":"Sequential administration of MVA-based vaccines and PD-1\/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-\u03b2Gal and MVA-MUC1 (TG4010) in a murine tumor model","volume":"14","author":"Remy-Ziller","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"15_suppl","key":"10.1016\/j.pccm.2026.08.001_bib0104","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e14637","article-title":"Phase I study of oncolytic virus (OV) MG1 maraba\/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced\/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214","volume":"35","author":"Jonker","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0105","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ymthe.2018.04.001","article-title":"Oncolytic virus combination therapy: killing one bird with two stones","volume":"26","author":"Martin","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.pccm.2026.08.001_bib0106","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1038\/s41467-021-22929-z","article-title":"Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination","volume":"12","author":"Roy","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.pccm.2026.08.001_bib0107","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1634\/theoncologist.2019-0608","article-title":"A phase I trial using a multitargeted recombinant adenovirus 5 (CEA\/MUC1\/brachyury)-based immunotherapy vaccine regimen in patients with advanced cancer","volume":"25","author":"Gatti-Mays","year":"2020","journal-title":"Oncologist"},{"issue":"15_suppl","key":"10.1016\/j.pccm.2026.08.001_bib0108","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9100","article-title":"Interim results of viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) in two treatment settings","volume":"39","author":"Cohen","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0109","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40425-017-0306-6","article-title":"A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer","volume":"5","author":"Sanborn","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"7_suppl","key":"10.1016\/j.pccm.2026.08.001_bib0110","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.7_suppl.110","article-title":"Long-term follow-up of DNA engineered bi-shRNA furin GMCSF plasmid\/autologous tumor induced immune response in patients with advanced solid tumors (phase I trial)","volume":"35","author":"Nemunaitis","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0111","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1182\/bloodadvances.2023009903","article-title":"Telomerase-targeted therapies in myeloid malignancies","volume":"7","author":"Waksal","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.pccm.2026.08.001_bib0112","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00262-019-02315-x","article-title":"A phase I\/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB\/IV non-small cell lung cancer","volume":"68","author":"Sebastian","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.pccm.2026.08.001_bib0113","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials of mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.pccm.2026.08.001_bib0114","first-page":"A691","article-title":"660 clinicopathologic characteristics of patients with metastatic colorectal cancer with molecular responses following treatment with an individualized neoantigen vaccine regimen","volume":"10","author":"Liao","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0115","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","article-title":"Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results","volume":"28","author":"Palmer","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.pccm.2026.08.001_bib0116","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","article-title":"A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer","volume":"183","author":"Ott","year":"2020","journal-title":"Cell"},{"issue":"Suppl 2","key":"10.1016\/j.pccm.2026.08.001_bib0117","first-page":"A515","article-title":"485 long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors","volume":"9","author":"Gillison","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"15_suppl","key":"10.1016\/j.pccm.2026.08.001_bib0118","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.2613","article-title":"Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors","volume":"39","author":"Gillison","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0119","doi-asserted-by":"crossref","first-page":"15","DOI":"10.33696\/immunology.6.188","article-title":"Personalized neoantigen DNA cancer vaccines: current status and future perspectives","volume":"6","author":"Viborg","year":"2024","journal-title":"J Cell Immunol"},{"issue":"13_Supplement","key":"10.1016\/j.pccm.2026.08.001_bib0120","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-CT217","article-title":"Abstract CT217: an open-label, phase I\/IIa study of VB10.NEO (DIRECT-01) in combination with checkpoint blockade in patients with locally advanced or metastatic solid tumors including melanoma, NSCLC, renal cell carcinoma, urothelial cancer or SSCHN","volume":"79","author":"Krauss","year":"2019","journal-title":"Cancer Res"},{"issue":"Suppl 2","key":"10.1016\/j.pccm.2026.08.001_bib0121","first-page":"A133","article-title":"117 integrative analyses of multiomics data and biomarker readout demonstrate clinical and immunological relevance of individualized vaccine design via the NeoSELECTTM platform","volume":"13","author":"Aure","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"12_Supplement","key":"10.1016\/j.pccm.2026.08.001_bib0122","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-4159","article-title":"Abstract 4159: lower doses of self-amplifying mRNA drive superior neoantigen-specific CD8+ T cell responses in cancer patients versus high doses","volume":"82","author":"Palmer","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.pccm.2026.08.001_bib0123","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1470-2045(11)70259-5","article-title":"Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial","volume":"12","author":"Quoix","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0124","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(15)00483-0","article-title":"TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b\/3 trial","volume":"17","author":"Quoix","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0125","article-title":"Autologous dendritic cell-based immunotherapy (DCVAC\/LuCa) and carboplatin\/paclitaxel in advanced non-small cell lung cancer: a randomized, open-label, phase I\/II trial","volume":"28","author":"Zemanova","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.pccm.2026.08.001_bib0126","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41568-024-00681-y","article-title":"Lymphatic vessels in the age of cancer immunotherapy","volume":"24","author":"Karakousi","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0127","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12943-025-02287-w","article-title":"Single-cell and spatial transcriptomic analyses revealing tumor microenvironment remodeling after neoadjuvant chemoimmunotherapy in non-small cell lung cancer","volume":"24","author":"Cui","year":"2025","journal-title":"Mol Cancer"},{"issue":"Suppl 3","key":"10.1016\/j.pccm.2026.08.001_bib0128","article-title":"Preliminary analysis of immune responses in patients enrolled in a phase II trial of cyclophosphamide with allogenic DRibble vaccine alone (DPV-001) or with GM-CSF or imiquimod for adjuvant treatment of stage IIIA or IIIB NSCLC","volume":"2","author":"Hilton","year":"2014","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0129","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2016.11.1190","article-title":"P2.02-043 randomized phase II trial of allogeneic DPV-001 cancer vaccine alone or with adjuvant for curatively-treated stage III NSCLC","volume":"12","author":"Sanborn","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"15_suppl","key":"10.1016\/j.pccm.2026.08.001_bib0130","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.e14639","article-title":"T cell population expansion in response to allogeneic cancer vaccine alone (DPV-001) or with granulocyte-macrophage colony-stimulating factor (GM-CSF) or imiquimod (I) for definitively-treated stage III NSCLC patients (pts)","volume":"35","author":"Fox","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0131","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41417-023-00587-1","article-title":"Clinical trials of self-replicating RNA-based cancer vaccines","volume":"30","author":"Morse","year":"2023","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.pccm.2026.08.001_bib0132","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1172\/JCI42672","article-title":"An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer","volume":"120","author":"Morse","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pccm.2026.08.001_bib0133","article-title":"Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum","volume":"5","author":"Ingels","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.pccm.2026.08.001_bib0134","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2023.09.985","article-title":"EP07.02-06 MIDRIXNEO-LUNG: safety and immunogenicity of a neoantigen-presenting autologous dendritic cell therapy in resected NSCLC patients","volume":"18","author":"Ingels","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0135","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.pccm.2024.11.003","article-title":"Neoadjuvant immunotherapy for non-small cell lung cancer: opportunities and challenges","volume":"2","author":"Hu","year":"2024","journal-title":"Chin Med J Pulm Crit Care Med"},{"key":"10.1016\/j.pccm.2026.08.001_bib0136","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results","volume":"31","author":"Wainberg","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.pccm.2026.08.001_bib0137","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/annonc\/mdv104","article-title":"Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses","volume":"26","author":"Mitchell","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0138","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","article-title":"Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial","volume":"15","author":"Butts","year":"2014","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.pccm.2026.08.001_bib0139","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.3036","article-title":"Phase I\/II study of tecemotide cancer immunotherapy for Japanese patients with unresectable stage III non-small cell lung cancer (NSCLC)","volume":"33","author":"Nokihara","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0140","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2017.01.007","article-title":"Phase I\/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer","volume":"105","author":"Katakami","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0141","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1071008","article-title":"Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC","volume":"5","author":"Besse","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.pccm.2026.08.001_bib0142","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0143","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jtho.2023.05.003","article-title":"Local treatments of oligometastatic and oligoprogressive NSCLC should become the standard of care","volume":"18","author":"Videtic","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"16_suppl","key":"10.1016\/j.pccm.2026.08.001_bib0144","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e21037","article-title":"Prognostic factors of overall survival (OS) in non-small cell lung cancer (NSCLC) patients after failure on immune checkpoint inhibitors (IO) treated with anticancer vaccine OSE2101 or chemotherapy (CT) in phase 3 ATALANTE-1 randomized trial","volume":"41","author":"Besse","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0145","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1158\/1078-0432.CCR-15-0855","article-title":"A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non\u2013small cell lung cancer patients","volume":"22","author":"Rodriguez","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pccm.2026.08.001_bib0146","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2023.07.006","article-title":"Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1","volume":"34","author":"Besse","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0147","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1287902","article-title":"Safety and effectiveness of CIMAvax-EGF administered in community polyclinics","volume":"13","author":"Ortiz Carrodeguas","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0148","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","article-title":"Oncogenic alterations in advanced NSCLC: a molecular super-highway","volume":"12","author":"Friedlaender","year":"2024","journal-title":"Biomark Res"},{"key":"10.1016\/j.pccm.2026.08.001_bib0149","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002891","article-title":"Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer","volume":"9","author":"Negrao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0150","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S1470-2045(24)00379-6","article-title":"Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis","volume":"25","author":"Zhao","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0151","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41698-021-00181-4","article-title":"A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer","volume":"5","author":"Gurule","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0152","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1158\/1078-0432.CCR-19-2027","article-title":"Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung cancer","volume":"26","author":"Isomoto","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pccm.2026.08.001_bib0153","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002531","article-title":"Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations","volume":"9","author":"Li","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"Supplement","key":"10.1016\/j.pccm.2026.08.001_bib0154","article-title":"P4.11D.05 EGFR neoantigen peptide vaccine combined with tislelizumab and chemotherapy for advanced NSCLC resistant to EGFR-TKI therapy","volume":"19","author":"Wang","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0155","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41586-025-08586-y","article-title":"Clonal driver neoantigen loss under EGFR TKI and immune selection pressures","volume":"639","author":"Al Bakir","year":"2025","journal-title":"Nature"},{"issue":"16_suppl","key":"10.1016\/j.pccm.2026.08.001_bib0156","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS2701","article-title":"First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors","volume":"40","author":"Pant","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0157","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41417-023-00717-9","article-title":"A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.pccm.2026.08.001_bib0158","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/s43018-023-00591-2","article-title":"ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer","volume":"4","author":"Mota","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0159","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00432-025-06115-y","article-title":"Advances in clinical research of MET exon 14 skipping mutations in non-small cell lung cancer","volume":"151","author":"Wang","year":"2025","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0160","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1624124","article-title":"HER2 alterations in non-small cell lung cancer (NSCLC): from biology and testing to advances in treatment modalities","volume":"15","author":"Ismail","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0161","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102906","article-title":"Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC","volume":"148","author":"Baraibar","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0162","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1238093","article-title":"Progress of non-small-cell lung cancer with ROS1 rearrangement","volume":"10","author":"Yang","year":"2023","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.pccm.2026.08.001_bib0163","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1033484","article-title":"Targeted therapy of RET fusion-positive non-small cell lung cancer","volume":"12","author":"Shen","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0164","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.18632\/oncotarget.2834","article-title":"PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies","volume":"6","author":"Scheffler","year":"2015","journal-title":"Oncotarget"},{"issue":"Suppl 3","key":"10.1016\/j.pccm.2026.08.001_bib0165","first-page":"A1716","article-title":"1486 Preliminary results from LuCa-MERIT-1, a phase I trial evaluating BNT116, a fixed antigen mRNA vaccine, plus cemiplimab in advanced non-small cell lung cancer after progression on PD-1 inhibition","volume":"12","author":"Atmaca","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0166","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.pccm.2026.08.001_bib0167","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.pccm.2026.08.001_bib0168","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.pccm.2026.08.001_bib0169","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70403","article-title":"Decoding MHC loss: molecular mechanisms and implications for immune resistance in cancer","volume":"15","author":"Lin","year":"2025","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.pccm.2026.08.001_bib0170","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12943-023-01899-4","article-title":"Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects","volume":"22","author":"Wu","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0171","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41577-025-01208-8","article-title":"Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development","volume":"26","author":"Huber","year":"2026","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0172","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.pccm.2026.08.001_bib0173","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1084\/jem.20160206","article-title":"pMHC affinity controls duration of CD8+ T cell-DC interactions and imprints timing of effector differentiation versus expansion","volume":"213","author":"Ozga","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.pccm.2026.08.001_bib0174","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.712488","article-title":"T cell epitope prediction and its application to immunotherapy","volume":"12","author":"Schaap-Johansen","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0175","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.4049\/jimmunol.1600582","article-title":"Pan-specific prediction of peptide\u2013MHC class I complex stability, a correlate of T cell immunogenicity","volume":"197","author":"Rasmussen","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0176","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cels.2020.06.010","article-title":"MHCflurry 2.0: improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing","volume":"11","author":"O\u2019Donnell","year":"2020","journal-title":"Cell Syst"},{"key":"10.1016\/j.pccm.2026.08.001_bib0177","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s42256-023-00694-6","article-title":"Deep neural networks predict class I major histocompatibility complex epitope presentation and transfer learn neoepitope immunogenicity","volume":"5","author":"Albert","year":"2023","journal-title":"Nat Mach Intell"},{"key":"10.1016\/j.pccm.2026.08.001_bib0178","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s42256-021-00383-2","article-title":"Deep learning-based prediction of the T cell receptor-antigen binding specificity","volume":"3","author":"Lu","year":"2021","journal-title":"Nat Mach Intell"},{"key":"10.1016\/j.pccm.2026.08.001_bib0179","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41587-019-0289-6","article-title":"Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes","volume":"37","author":"Racle","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0180","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41587-019-0280-2","article-title":"Predicting HLA class II antigen presentation through integrated deep learning","volume":"37","author":"Chen","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0181","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s41422-025-01199-0","article-title":"Harnessing alternative splicing for off-the-shelf mRNA neoantigen vaccines in hepatocellular carcinoma","volume":"35","author":"Zhao","year":"2025","journal-title":"Cell Res"},{"key":"10.1016\/j.pccm.2026.08.001_bib0182","article-title":"Bright side of the dark genome: antigens for next-gen cancer vaccines","volume":"14","author":"Wang","year":"2026","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0183","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s43018-025-00979-2","article-title":"Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer","volume":"6","author":"Apavaloaei","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0184","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abm6359","article-title":"Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer","volume":"8","author":"Merlotti","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0185","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3390\/pharmaceutics14071515","article-title":"Development of a personalized tumor neoantigen based vaccine formulation (FRAME-001) for use in a phase II trial for the treatment of advanced non-small cell lung cancer","volume":"14","author":"Oosting","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pccm.2026.08.001_bib0186","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012217","article-title":"Shared epitopes create safety and efficacy concerns in several cancer vaccines","volume":"13","author":"Kellermann","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0187","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res"},{"key":"10.1016\/j.pccm.2026.08.001_bib0188","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41586-025-09903-1","article-title":"Intratumoural vaccination via checkpoint degradation-coupled antigen presentation","volume":"650","author":"Han","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.pccm.2026.08.001_bib0189","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0190","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.pccm.2026.08.001_bib0191","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/14760584.2024.2303015","article-title":"Neoadjuvant personalized cancer vaccines: the final frontier?","volume":"23","author":"Richard","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.pccm.2026.08.001_bib0192","article-title":"Prospects and challenges of lung cancer vaccines","volume":"13","author":"Lin","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.pccm.2026.08.001_bib0193","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1159\/000543556","article-title":"Characteristics and risk factors of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: a retrospective study","volume":"103","author":"Cui","year":"2025","journal-title":"Oncology"},{"key":"10.1016\/j.pccm.2026.08.001_bib0194","doi-asserted-by":"crossref","first-page":"S582","DOI":"10.1016\/j.jtho.2021.01.1053","article-title":"P75.19 investigation of lung cancer patients receiving immunotherapy with pre-existing lung disease","volume":"16","author":"Mcgovern","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0195","doi-asserted-by":"crossref","DOI":"10.1200\/OA-25-00008","article-title":"Three-year update of a randomized phase IIb study of the individualized neoantigen therapy intismeran autogene (mRNA-4157, V940) plus pembrolizumab versus pembrolizumab in resected melanoma","volume":"3","author":"Carlino","year":"2026","journal-title":"JCO Oncol Adv"},{"key":"10.1016\/j.pccm.2026.08.001_bib0196","doi-asserted-by":"crossref","first-page":"41600","DOI":"10.18632\/oncotarget.6113","article-title":"Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies","volume":"6","author":"Gebremeskel","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.pccm.2026.08.001_bib0197","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40425-019-0549-5","article-title":"Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines?","volume":"7","author":"M\u00e9n\u00e9trier-Caux","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0198","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251316988","article-title":"Impact of systemic anticancer therapy timing on cancer vaccine immunogenicity: a review","volume":"17","author":"Gomez-Randulfe","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0199","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2022.01.007","article-title":"Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy","volume":"168","author":"Cho","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0200","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41568-025-00903-x","article-title":"Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy","volume":"26","author":"Darragh","year":"2026","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0201","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41586-026-10243-x","article-title":"Thymic health and immunotherapy outcomes in patients with cancer","volume":"652","author":"Bernatz","year":"2026","journal-title":"Nature"},{"issue":"7_Supplement","key":"10.1016\/j.pccm.2026.08.001_bib0202","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2026-2327","article-title":"Abstract 2327: thymic radiation and oncologic outcomes","volume":"86","author":"Prudente","year":"2026","journal-title":"Cancer Res"},{"key":"10.1016\/j.pccm.2026.08.001_bib0203","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.pccm.2026.08.001_bib0204","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.lungcan.2007.04.002","article-title":"Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells","volume":"57","author":"Hirschowitz","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.pccm.2026.08.001_bib0205","doi-asserted-by":"crossref","first-page":"6731","DOI":"10.1038\/s41467-023-42417-w","article-title":"DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts","volume":"14","author":"Goyal","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.pccm.2026.08.001_bib0206","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1158\/2326-6066.CIR-21-0806","article-title":"CDK2 inhibition enhances antitumor immunity by increasing IFN response to endogenous retroviruses","volume":"10","author":"Chen","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.pccm.2026.08.001_bib0207","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41698-025-00984-9","article-title":"A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer","volume":"9","author":"Boukouris","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0208","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2026.116729","article-title":"A phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours","volume":"240","author":"Robert","year":"2026","journal-title":"Eur J Cancer"},{"issue":"7_Supplement","key":"10.1016\/j.pccm.2026.08.001_bib0209","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-CT051","article-title":"Abstract CT051: preliminary results from LuCa-MERIT-1, a first-in-human phase I trial evaluating the fixed antigen mRNA vaccine BNT116 + docetaxel in patients with advanced non-small cell lung cancer","volume":"84","author":"\u00d6ven","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.pccm.2026.08.001_bib0210","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.jtho.2025.09.102","article-title":"MA01.07 preliminary results of the phase I LuCa-MERIT-1 trial: an advanced NSCLC pt cohort treated with BNT116 + cemiplimab post CRT","volume":"20","author":"\u00d6ven","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.pccm.2026.08.001_bib0211","first-page":"A679","article-title":"597 preliminary results from LuCa-MERIT-1, a first-in-human phase I trial evaluating the fixed antigen RNA vaccine BNT116 in patients with advanced non-small cell lung cancer","volume":"11","author":"Deme","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"16_suppl","key":"10.1016\/j.pccm.2026.08.001_bib0212","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.9135","article-title":"Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC)","volume":"41","author":"Frascati","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pccm.2026.08.001_bib0213","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103717","article-title":"Survivin recombinant overlapping peptide (ROP) vaccine in advanced solid tumours: a first-in-human, multicentre, open-label, phase 1a dose-escalation study","volume":"91","author":"Wijaya","year":"2026","journal-title":"eClinicalMedicine"}],"container-title":["Chinese Medical Journal Pulmonary and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772558826000460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772558826000460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:41:38Z","timestamp":1790692898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772558826000460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":213,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2772558826000460"],"URL":"https:\/\/doi.org\/10.1016\/j.pccm.2026.08.001","relation":{},"ISSN":["2772-5588"],"issn-type":[{"value":"2772-5588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic vaccines for NSCLC: From mechanisms to clinical translation","name":"articletitle","label":"Article Title"},{"value":"Chinese Medical Journal Pulmonary and Critical Care Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pccm.2026.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V. on behalf of Chinese Medical Association.","name":"copyright","label":"Copyright"}]}}